Uniting Wealth Partners LLC Acquires Shares of 27,339 Pfizer Inc. (NYSE:PFE)

Uniting Wealth Partners LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 27,339 shares of the biopharmaceutical company's stock, valued at approximately $725,000.

Other hedge funds have also added to or reduced their stakes in the company. Arete Wealth Advisors LLC raised its stake in shares of Pfizer by 34.0% during the fourth quarter. Arete Wealth Advisors LLC now owns 86,772 shares of the biopharmaceutical company's stock valued at $2,299,000 after acquiring an additional 22,013 shares during the last quarter. World Investment Advisors increased its holdings in Pfizer by 5.6% in the fourth quarter. World Investment Advisors now owns 134,378 shares of the biopharmaceutical company's stock valued at $3,565,000 after purchasing an additional 7,113 shares during the period. Westpac Banking Corp raised its position in Pfizer by 38.4% during the 4th quarter. Westpac Banking Corp now owns 102,671 shares of the biopharmaceutical company's stock worth $2,724,000 after purchasing an additional 28,473 shares during the last quarter. OneAscent Financial Services LLC lifted its holdings in Pfizer by 44.8% during the 4th quarter. OneAscent Financial Services LLC now owns 36,999 shares of the biopharmaceutical company's stock worth $982,000 after buying an additional 11,447 shares during the period. Finally, Cinctive Capital Management LP grew its position in shares of Pfizer by 7.1% in the 4th quarter. Cinctive Capital Management LP now owns 181,302 shares of the biopharmaceutical company's stock valued at $4,810,000 after buying an additional 12,060 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on PFE shares. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Stock Down 1.6 %

PFE stock traded down $0.41 during trading on Thursday, reaching $24.30. 53,412,700 shares of the stock were exchanged, compared to its average volume of 39,310,365. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.26 and a twelve month high of $31.54. The firm's 50 day moving average is $25.93 and its 200 day moving average is $26.81. The firm has a market cap of $137.79 billion, a P/E ratio of 17.23, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.